Sunitinib as a paradigm for tyrosine kinase inhibitor development for renal cell carcinoma
Author:
Publisher
Elsevier BV
Subject
Urology,Oncology
Reference33 articles.
1. Cancer statistics, 2013;Siegel;CA Cancer J Clin,2013
2. Renal cancer: molecular mechanisms and newer therapeutic options;Karumanchi;Curr Opin Nephrol Hypertens,2002
3. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis;Maxwell;Nature,1999
4. VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400;Young;Nat Cell Biol,2008
5. Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth;Kondo;PLoS Biol,2003
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Poly(ADP)-Ribosylation Inhibition: A Promising Approach for Clear Cell Renal Cell Carcinoma Therapy;Cancers;2021-10-03
2. GU ONCOLOGY;Cancer;2019-09-09
3. Exploring the binding interaction between herring sperm DNA and sunitinib: insights from spectroscopic and molecular docking approaches;Journal of Biomolecular Structure and Dynamics;2018-03-01
4. Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases;Journal of Pharmacology and Experimental Therapeutics;2017-12-20
5. Waist-hip Ratio (WHR), a Better Predictor for Prostate Cancer than Body Mass Index (BMI): Results from a Chinese Hospital-based Biopsy Cohort;Scientific Reports;2017-03-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3